MedTrace Logo

Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550

NCT01059864 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2012-12-13

Study results available
· View outcomes & findings →

Summary

All patients will be in instructed to eat a therapeutic lifestyle diet and will receive CP-690,550 throughout the 12 weeks of this study. After 6 weeks, half will receive the cholesterol lowering agent, atorvastatin, and half a matching placebo. This study will first measure the effects of CP-690,550 on cholesterol levels and then the effects of adding atorvastatin on those levels.

Conditions

Interventions

DRUG

CP-690,550

12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12

DRUG

Atorvastatin

Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily

DRUG

CP-690,550

12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12

DRUG

Atorvastatin Placebo

Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01059864 on ClinicalTrials.gov